NASDAQ:CLNN Clene Q2 2026 Earnings Report $4.10 +0.04 (+0.99%) Closing price 09/29/2026 04:00 PM EasternExtended Trading$4.26 +0.16 (+3.98%) As of 06:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Clene EPS ResultsActual EPS-$1.08Consensus EPS -$0.37Beat/MissMissed by -$0.71One Year Ago EPSN/AClene Revenue ResultsActual Revenue$0.09 millionExpected Revenue$0.06 millionBeat/MissBeat by +$29.00 thousandYoY Revenue GrowthN/AClene Announcement DetailsQuarterQ2 2026Date8/14/2026TimeBefore Market OpensConference Call DateFriday, August 14, 2026Conference Call Time7:00AM ETUpcoming EarningsClene's Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Clene Earnings HeadlinesReviewing Harrow (NASDAQ:HROW) & Clene (NASDAQ:CLNN)1 hour ago | americanbankingnews.comComparing Evolus (NASDAQ:EOLS) and Clene (NASDAQ:CLNN)2 hours ago | americanbankingnews.comWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned.September 30 at 1:00 AM | Awesomely (Ad)Clene to Present at Upcoming Investor ConferencesSeptember 22, 2026 | globenewswire.comClene Announces Closing of $4 Million Registered Direct Offering Extending Capital Runway Beyond FDA Decision on CNM-Au8® NDASeptember 21, 2026 | globenewswire.comArcutis Biotherapeutics (NASDAQ:ARQT) vs. Clene (NASDAQ:CLNN) Critical SurveySeptember 20, 2026 | americanbankingnews.comSee More Clene Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Clene? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Clene and other key companies, straight to your email. Email Address About CleneClene (NASDAQ:CLNN) (NASDAQ: CLNN) is a clinical-stage biopharmaceutical company focused on developing nanotherapeutics for neurodegenerative diseases. The company’s platform uses nanocrystals designed to influence cellular energy production and protect or restore the function of nerve cells. Clene’s leading investigational product is CNM-Au8, an orally administered suspension containing catalytically active gold nanocrystals. The therapy is being evaluated in clinical studies for conditions including amyotrophic lateral sclerosis (ALS), multiple sclerosis and Parkinson’s disease. Clene’s research programs are aimed at addressing underlying cellular energy deficits that may contribute to neurodegeneration. Founded in 2013, Clene is headquartered in Salt Lake City, Utah, and conducts its research and clinical development activities through collaborations and clinical trials involving patients in the United States and other regions. The company’s chief executive officer is Rob Etherington, who has led Clene’s efforts to advance its nanotherapeutics platform and clinical programs.View Clene ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles CarMax Just Gave Investors a Better Reason to Believe in the TurnaroundBernstein Downgrades 3 Cybersecurity Stocks: How Concerned Should Investors Be?Brewing Trouble? Starbucks Spills the Beans on 250 Store ClosuresMarketBeat Week in Review – 09/21 - 09/25Analyst Rating Boosts May Signal More Upside for These 3 Stocks3 Stocks Under the Microscope After Large Insider Sales3 Healthcare Stocks Showing Why the Sector Still Has Momentum Upcoming Earnings NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
